I am super sad…we lost about 600 holders today.
People see red and they become afraid, think $CHOO is just like the rest.
They've been burned so much that they are conditioned to be fearful, never fully trusting any projects.
How could you blame them?
I know it's hard to trust, and we don't blame you.
CHOO will never go to zero.
We have too many eyes watching.
Too many that believe.
Founders who won't stop shipping.
Major media dropping.
Supply being burned daily.
Full blowN cartoon series in the making.
Daily CHOO, CHOO-able's, and CHOO Toys in production.
SUPER-DOG beds dropping.
Huge deals with bigtime authority figures in the works.
I just hope you didn't sell for a loss because you see a red market and are afraid CHOO will go to zero … because my dad will never quit on this.
DMs are open if you need someone to talk to during the downturn.
Brighter days ahead.
Thank you for ChooLieving.
Who would've thought you could literally biohack your and your dog's health with a meme?
solana:EJAxERvKU4kEVXn3NarjvRtgaMaJyP9ZuMeKA7JJpump utility is about to go even crazier ↓
The changes in $CHOO fundamentals go beyond simply adding another advisor.
EJAxERvKU4kEVXn3NarjvRtgaMaJyP9ZuMeKA7JJpump
The market's understanding of the project is expanding from a pet health meme toward a crypto-native project in the Peptides & Biotech sector.
The market is starting to price in a bigger story.
Here are my thoughts.
I believe CHOO's fundamentals are continuing to strengthen, and this development is more significant than when Ogle first joined as an advisor. Ogle brought attention and credibility from the pet health industry, while MoneyPrinter0x's arrival is allowing the market to view CHOO from the much broader perspective of Peptides & Biotech.
This is no longer just an animal meme built around a rescued dog. It's a crypto-native project attempting to connect real-world peptide products, pet health consumption, and the crypto market.
Let's start with MoneyPrinter.
He is known in the crypto market for his contrarian calls and ability to identify asymmetric opportunities. CHOO's official account specifically highlighted some of his previous calls, including INTC at around $20.5, BB at $5, SOL at $255, BTC at $58K, as well as Zai and HYPE.
These calls alone cannot be treated as a complete or audited investment track record. What matters more is why he chose to join CHOO.
He believes Peptides & Biotech could become the next market sector worth paying attention to after AI. He compares this opportunity to the Agentic AI wave on Solana in 2024, when capital and attention shifted from traditional memes toward AI Agent projects with product narratives.
Now, he believes a similar rotation could happen in Bio and Peptides, with CHOO being the on-chain project he has chosen to participate in.
I think this is the most important change in the latest update.
Previously, CHOO's narrative mainly revolved around a rescued dog, pet health, and Pawgen. Now, it has an opportunity to expand into the much broader Peptides narrative.
However, I wouldn't directly classify CHOO as a mature RWA project at this stage. Token holders do not own equity in Pawgen, rights to its product inventory, or a share of its sales revenue. For now, it's better understood as an attempt to connect real-world product consumption with an on-chain token. Whether this can eventually form a genuine business model is the key question.
Looking at the market participants, there are also some changes.
Following Ogle's previous appointment, MoneyPrinter has now joined the advisory team, and the project has also received public support from Ansem.
TJR also mentioned that Ansem had purchased CHOO. These signals have further increased the market's attention toward the project.
In addition, TJR previously shared his personal position of approximately 14.7M CHOO, worth around $79.8K at the time, with unrealized profits of approximately $61.9K and a return of around 345%.
Meanwhile, the official account announced that CHOO had reached the Top 3 on FOMO's trending list, with 24-hour trading volume exceeding $5M.
This means the project is no longer relying solely on the founder to tell its story. More traders and social media accounts are starting to actively spread the word.
Of course, there's one trading detail worth noting: early participants have already accumulated considerable unrealized profits. This can attract new capital, but those profits could also turn into selling pressure later. So I'd rather view these developments as an increase in market attention and distribution, rather than proof that long-term holder conviction has already formed.
Beyond that, the project itself is continuing to build.
Pawgen has already launched K9-REPAIR, establishing a real product sales channel around pet health and recovery management. The website is also planning PawScript, attempting to provide long-term pet health management through at-home sampling, veterinary technician involvement, testing across 47 biological indicators, and PawScore health assessments.
This is worth paying attention to.
If Pawgen only sells one product, its commercial potential is relatively limited. But if it can eventually build a complete service system covering testing, health assessments, personalized plans, and repeat purchases, the business could expand from one-time product sales into a long-term customer relationship.
PawScript is still marked as Coming Soon on the website, so we shouldn't treat it as a business that is already generating revenue. The website also mentions that 1% of every product sale will go toward building Choo the Rescue to help other dogs in need. This further connects the project's mission with its actual commercial activities.
I think CHOO's biggest difference is that it hasn't remained purely at the level of a brand story. It's attempting to bring the token into actual consumer transactions.
According to the website, users can purchase Pawgen products with CHOO and receive a discount, while the tokens used for payment enter the burn process. This gives real product consumption the opportunity to become a source of actual token demand, rather than relying solely on traders buying and selling among themselves.
The website currently shows approximately 1.19M tokens burned, representing around 0.12% of the initial 1 billion supply. The mechanism has already been used in practice, but there is still a long way to go before it creates meaningful supply contraction.
Looking ahead, there are several potential catalysts I believe are worth watching.
First, whether Peptides & Biotech can become a sustained narrative in the crypto market. If capital and attention really rotate from AI toward Bio and Peptides, CHOO could have an opportunity to gain a much broader narrative than an ordinary animal meme.
Second, whether the advisory team can bring in actual resources. Ogle and MoneyPrinter have already increased the project's exposure across CT. If more people with relevant industry experience join and start contributing to partnerships, market expansion, and product development, the advisory team could eventually become a meaningful long-term asset rather than just a marketing advantage.
Third, Pawgen's actual sales and repeat purchases. If K9-REPAIR continues generating orders, the proportion of purchases made with CHOO increases, and on-chain burns grow accordingly, the market will have a much clearer picture of how real-world consumption translates into token demand.
The risks are also worth noting.
Previous on-chain data showed that seven wallets held approximately 79.3% of the supply shortly after launch. Although the tokens were subsequently transferred to more addresses, this does not prove that those wallets were controlled by the same entity. However, it does mean that the early token distribution structure needs to be monitored.
Having advisors, products, and a real story does not mean the token is free from concentrated selling pressure.
The regulatory and product safety issues within the Peptides sector could also directly affect Pawgen's long-term development.
Overall, I remain objectively bullish on CHOO, and I believe its fundamentals have taken another step forward compared with my previous analysis.
Last time, we mainly discussed why Ogle chose to get involved and whether Pawgen could turn the story of a real rescued dog into a pet health brand.
This time, MoneyPrinter's arrival has brought CHOO into the much broader Peptides & Biotech narrative. Combined with the increased attention across CT, reports of Ansem buying, and the product payment burns that have already taken place, the market's attention is no longer limited to a single rescued dog.
What I'm more willing to bet on is not how many more advisors CHOO can add, but whether Pawgen can continue selling products, whether consumers will actually use CHOO to pay for them, and whether that consumption can generate verifiable on-chain demand.
If CHOO ultimately relies only on advisors and market attention to sustain trading activity, it will remain an attention-driven meme. But if Pawgen can establish consistent real-world consumer demand, it has an opportunity to evolve from an animal meme into a broader narrative connecting Peptides & Biotech with crypto.
Chart: https://t.co/bj3M1y2DLi